Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease; 2014 [updated 2015] Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdfAccessed Jan 17, 2015
   Google Scholar
• VestboJEdwardsLDScanlonPDECLIPSE InvestigatorsChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med2011365131184119221991892
   PubMed Web of Science ®Google Scholar
• BuistASMcBurnieMAVollmerWMBOLD Collaborative Research GroupInternational variation in the prevalence of COPD (the BOLD Study): a population-based prevalence studyLancet2007370958974175017765523
   PubMed Web of Science ®Google Scholar
• MenezesAMPerez-PadillaRJardimJRPLATINO TeamChronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence studyLancet200536695001875188116310554
   PubMed Web of Science ®Google Scholar
• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2006311e44217132052
   PubMed Web of Science ®Google Scholar
• NishimuraKIzumiTTsukinoMOgaTDyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPDChest200212151434144012006425
   PubMed Web of Science ®Google Scholar
• PittaFTroostersTSpruitMAProbstVSDecramerMGosselinkRCharacteristics of physical activities in daily life in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2005171997297715665324
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJMartínez-GarcíaMARomán SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• ManninoDMThornDSwensenAHolguinFPrevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPDEur Respir J200832496296918579551
   PubMed Web of Science ®Google Scholar
• BarnesPJCelliBRSystemic manifestations and comorbidities of COPDEur Respir J20093351165118519407051
   PubMed Web of Science ®Google Scholar
• CopeSDonohueJFJansenJPComparative efficacy of long-acting bronchodilators for COPD: a network meta-analysisRespir Res201314110024093477
   PubMedGoogle Scholar
• WedzichaJADecramerMSeemungalTAThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J20124061545155422835613
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSLystigTMehraSTashkinDPUPLIFT investigatorsEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
   PubMed Web of Science ®Google Scholar
• SethiSCoteCBronchodilator combination therapy for the treatment of chronic obstructive pulmonary diseaseCurr Clin Pharmacol201161486121235463
   PubMedGoogle Scholar
• US Food Drug AdministrationFDA approves Anoro Ellipta to treat chronic obstructive pulmonary diseaseSilver Spring, MDUS Food and Drug Administration2013 Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm379057.htmAccessed Jan 17, 2015
   Google Scholar
• European Medicines AgencyAnoroLondonEuropean Medicines Agency2014 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002751/human_med_001754.jsp&mid=WC0b01ac058001d124Accessed
   Google Scholar
• BeehKMBeierJThe short, the long and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary diseaseAdv Ther201027315015920411368
   PubMed Web of Science ®Google Scholar
• LangePMarottJLVestboJPrediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general populationAm J Respir Crit Care Med20121861097598122997207
   PubMed Web of Science ®Google Scholar
• AgustiAHurdSJonesPFAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohortsEur Respir J20134251391140123645406
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnstPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax201368111029103624130228
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD01011524615270
   PubMed Web of Science ®Google Scholar
• CorradoARossiAHow far is real life from COPD therapy guidelines? An Italian observational studyRespir Med2012106798999722483189
   PubMed Web of Science ®Google Scholar
• RossiAGuerrieroMCorradoAOPTIMO/AIPO Study GroupWithdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respir Res2014157725005873
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWISDOM InvestigatorsWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLM2-127 and M2-128 study groupsRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• CalverleyPMRabeKFGoehringUMKristiansenSFabbriLMMartinezFJM2-124 and M2-125 study groupsRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• MeursHDekkersBGMaarsinghHHalaykoAJZaagsmaJGosensRMuscarinic receptors on airway mesenchymal cells: novel findings for an ancient targetPulm Pharmacol Ther201326114515522842340
   PubMed Web of Science ®Google Scholar
• UndemBJKollarikMThe role of vagal afferent nerves in chronic obstructive pulmonary diseaseProc Am Thorac Soc20052435536016267362
   PubMedGoogle Scholar
• PowrieDJWilkinsonTMDonaldsonGCEffect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPDEur Respir J200730347247817504798
   PubMed Web of Science ®Google Scholar
• PeraTZuidhofAValadasJTiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPDEur Respir J201138478979621349917
   PubMed Web of Science ®Google Scholar
• CostaLRothMMiglinoNTiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathwayPulm Pharmacol Ther2014271293724269928
   PubMed Web of Science ®Google Scholar
• PriceDLeeAJSimsEJCharacteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort studyPrim Care Respir J201322216116823460035
   PubMedGoogle Scholar
• Tal-SingerRCahnAMehtaRInitial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studiesEur J Pharmacol20137011–3404823276660
   PubMed Web of Science ®Google Scholar
• TrivediRRichardNMehtaRChurchAUmeclidinium in patients with COPD: a randomised, placebo-controlled studyEur Respir J2014431728123949963
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• ProcopiouPABarrettVJBevanNJSynthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approachJ Med Chem201053114522453020462258
   PubMed Web of Science ®Google Scholar
• KempsfordRNorrisVSiedererSVilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPDPulm Pharmacol Ther201326225626423232038
   PubMed Web of Science ®Google Scholar
• HananiaNAFeldmanGZachgoWThe efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialChest2012142111912722241764
   PubMed Web of Science ®Google Scholar
• KelleherDTombsLPreeceABrealeyNMehtaRA randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjectsPulm Pharmacol Ther2014291495725020273
   PubMed Web of Science ®Google Scholar
• FeldmanGWalkerRRBrooksJMehtaRCraterG28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trialPulm Pharmacol Ther201225646547122955035
   PubMed Web of Science ®Google Scholar
• DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res2014157825015176
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce – Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD. A Randomized, Controlled StudyChest20141455981991
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis20148616918125452426
   PubMed Web of Science ®Google Scholar
• SinghDWorsleySZhuCQUmeclidinium/vilanterol (UMEC/VIL) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbationsEur Respir J201444Suppl 58P290
   Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• MaltaisFBeckEWebsterDFour weeks once daily treatment with tiotropium olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients (abstract no. P5557)Eur Respir J201036suppl 541014s
   Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of acli-dinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med201414117825404569
   PubMed Web of Science ®Google Scholar
• ReisnerCFogartyCSpangenthalSNovel combination of glycopyrrolate and formoterol Mdi (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized,double-blind, placebo-controlled Phase 2b study in patients with COPD [abstract]Am J Respir Crit Care Med20111831A6435
   Google Scholar